Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentylenetetrazol SCHEMBL9838533 | 0.70 | ALDH1A1 (1.00) | MEN1ALDH1A1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL22674 | 0.70 | ALDH1A1 (1.00) | MEN1ALDH1A1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL6407957 | 0.70 | ALDH1A1 (1.00) | MEN1ALDH1A1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL28326199 | 0.69 | ALDH1A1 (0.88) | MEN1ALDH1A1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL10873243 | 0.68 | ALDH1A1 (0.96) | MEN1ALDH1A1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL15057132 | 0.68 | ALDH1A1 (0.96) | MEN1ALDH1A1MAPTBLMKMT2A | |
| SCHEMBL13895514 | 0.65 | MEN1 (0.52) | MEN1ALDH1A1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL18501328 | 0.61 | MEN1 (0.47) | MEN1ALDH1A1MAPTBLMKMT2A | |
| SCHEMBL10932455 | 0.60 | TRIM24 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL4650647 | 0.60 | TRIM24 (0.41) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951076-B2 | Deuterated pentylenetetrazoles for improving cognitive function | BALANCE THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951076-B2 | Deuterated pentylenetetrazoles for improving cognitive function | BALANCE THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170044165-A1 | PENTYLENETETRAZOLE DERIVATIVES | EMORY UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| US-20170044165-A1 | PENTYLENETETRAZOLE DERIVATIVES | EMORY UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| US-20170044165-A1 | PENTYLENETETRAZOLE DERIVATIVES | EMORY UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| US-9453020-B2 | Substituted pentylenetetrazoles as GABA receptor activity modulators | BALANCE THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453020-B2 | Substituted pentylenetetrazoles as GABA receptor activity modulators | BALANCE THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453020-B2 | Substituted pentylenetetrazoles as GABA receptor activity modulators | BALANCE THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2705013-B1 | PENTYLENETETRAZOLE DERIVATIVES | BALANCE THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140343040-A1 | PENTYLENETETRAZOLE DERIVATIVES | EMORY UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20140343040-A1 | PENTYLENETETRAZOLE DERIVATIVES | EMORY UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20140343040-A1 | PENTYLENETETRAZOLE DERIVATIVES | EMORY UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| EP-2705013-A1 | PENTYLENETETRAZOLE DERIVATIVES | Balance Therapeutics, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151343-A1 | PENTYLENETETRAZOLE DERIVATIVES | BALANCE THERAPEUTICS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151343-A1 | PENTYLENETETRAZOLE DERIVATIVES | BALANCE THERAPEUTICS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343040-A1 | PENTYLENETETRAZOLE DERIVATIVES | SENP7, ACHE, CHRNA9 | MEN1 305/4885ALDH1A1 3228/4885MAPT 111/4885 |
| US-20170044165-A1 | PENTYLENETETRAZOLE DERIVATIVES | SENP7, ACHE, CHRNA9 | MEN1 305/4885ALDH1A1 3228/4885MAPT 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.